Relating Clinical Trials to Psychiatric Practice: Part II: The Gap between the Usual Patient in Registration Trials and in Practice

Journal of Psychiatric Practice

Volumn 9, Issue 6, 2003, Pages 455-461

  Preskorn, Sheldon H ^a,b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^b University of Kansas School of Medicine Wichita Psychiatric Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CHLORAL HYDRATE; CLOZAPINE; DRUG; FLUOXETINE; LITHIUM; MONOAMINE OXIDASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; ZOLPIDEM;

AGRANULOCYTOSIS; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG APPROVAL; DRUG CLEARANCE; DRUG DESIGN; DRUG EFFECT; DRUG FATALITY; DRUG MARKETING; DRUG METABOLISM; DRUG OVERDOSE; DRUG RESEARCH; HUMAN; INFORMED CONSENT; LIVER FAILURE; MANIA; MATHEMATICAL ANALYSIS; PATIENT SELECTION; PSYCHIATRY; REGISTRATION; REVIEW; SEIZURE; SEROTONIN SYNDROME; SUICIDE;

EID: 0344304743     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/00131746-200311000-00008     Document Type: Review

References (36)

1. Preskorn SH. Relating clinical trials to psychiatric practice: Part I: The case of a 13-year old on aripiprazole and fluoxetine. Journal of Psychiatric Practice 2003;9:307-13.
2. Preskorn SH. Modern drug development and the human genome project. Series of columns published in the Journal of Psychiatric Practice between 2000 and 2002.
3. Preskorn SH. The stages of drug development and the human genome project: Drug discovery. Journal of Psychiatric Practice 2000;6:341-4.
4. Offord SJ, Wong DF, Nyberg S. The role of positron emission tomography in the drug development of M100907, a putative antipsychotic with a novel mechanism of action. J Clin Pharmacol 1999;Aug (suppl):17S-24S.
5. Kuhlmann J, Muck W. Clinical-pharmacological strategies to assess drug interaction potential during drug development. Drug Saf 2001;24:715-25.
6. Preskorn SH. The rationale for and clinical implications of dose-response curves. Series of columns published in the Journal of Practical Psychiatry and Behavioral Health in 1996.
7. Preskorn SH. Reproducibility of the in vivo effect of the selective serotonin reuptake inhibitors on the in vivo function of cytochrome P450 2D6: An update (part II). Journal of Psychiatric Practice 2003;9:228-36.
8. Evans WE, Johnson JA. Pharmacogenomics: The inherited basis for interindividual differences in drug response. Annu Rev Genomics Hum Genet 2001;2:9-39.
9. Herrmann SM, Nicaud V, Tiret L, et al. Polymorphisms of the beta2-adrenoceptor (ADRB2) gene and essential hypertension: The ECTIM and PEGASE studies. J Hypertens 2002;20:229-35.
10. Gingrich JA. Mutational analysis of the serotonergic system: Recent findings using knockout mice. Curr Drug Target CNS Neurol Disord 2002;1:449-65.
11. Siest G, Ferrari L, Accaoui MJ, et al. Pharmacogenomics of drugs affecting the cardiovascular system. Clin Chem Lab Med. 2003;41:590-9.
12. Brunner HG, Nelen M, Breakefield XO, et al. Abnormal behavior associated with a point mutation in the structural gene for monoamine oxidase A. Science 1993;262:578-80.
13. Schuback DE, Mulligan EL, Sims KB, et al. Screen for MAOI mutations in target human groups. Am J Med Genet 1999;88:25-8.
14. Shih JC, Chen K, Ridd MJ. Monoamine oxidase: From genes to behavior. Annu Rev Neurosci 1999;22:197-217.
15. Shih JC, Thompson RF. Monoamine oxidase in neuropsychiatry and behavior. Am J Hum Genet 1999;65:593-8.
16. Preskorn SH. The overlap of DSM-IV syndromes: Potential implications for the practice of polypsychopharmacology, psychiatric drug development, and the human genome project. Journal of Psychiatric Practice 2002;8:170-7.
17. Treatment with antidepressants. In: Janicak P, Davis JM, Preskorn SH, et al. Principles and practice of psychopharmacotherapy, 3rd edition. Philadelphia: Lippincott Williams & Wilkins; 2001:215-325.
18. Preskorn SH. "A dangerous idea." Journal of Practical Psychiatry and Behavioral Health 1996;2:231-4.
19. Preskorn SH. Patients don't fail treatments, treatments fail patients. Journal of Practical Psychiatry and Behavioral Health 1997;3:165-8.
20. Kuhlmann J. Alternative strategies in drug development: Clinical pharmacological aspects. Int J Clin Pharmacol Ther 1999;37:575-83.
21. Chaikin P, Rhodes GR, Bruno R, et al. Pharmacokinetics/pharmacodynamics in drug development: An industrial perspective. J Clin Pharmacol 2000;40:1428-38.
22. Caldwell GW, Ritchie DM, Masucci JA, et al. The new pre-preclinical paradigm: Compound optimization in early and late phase drug discovery. Curr Top Med Chem 2001;1:353-66.
23. DiMasi JA. The value of improving the productivity of the drug development process: Faster times and better decisions. Pharmacoeconomics. 2002;20 (Suppl 3):1-10.
24. Code of Federal Regulations: ICH Guideline for Good Clinical Practice Title 21: Food and Drugs, April 1, 2003
25. Rodrigues AD, Rushmore TH. Cytochrome P450 pharmacogenetics in drug development: In vitro studies and clinical consequences. Curr Drug Metab 2002;3:289-309.
26. Bu HZ, Magis L, Knuth K, et al. High-throughput cytochrome P450 (CYP) inhibition screening via a cassette probe-dosing strategy. VI. Simultaneous evaluation of inhibition potential of drugs on human hepatic isozymes CYP2A6, 3A4, 2C9, 2D6 and 2E1. Rapid Commun Mass Spectrom 2001;15:741-8.
27. Masimirembwa CM, Thompson R, Andersson TB. In vitro high throughput screening of compounds for favorable metabolic properties in drug discovery. Comb Chem High Throughput Screen 2001;4:245-63.
28. Riley RJ, Parker AJ, Trigg S, et al. Development of a generalized, quantitative physicochemical model of CYP3A4 inhibition for use in early drug discovery. Pharm Res 2001;18:652-5.
29. Bonnabry P, Sievering J, Leemann T, et al. Quantitative drug interactions prediction system (Q-DIPS): A dynamic computer-based method to assist in the choice of clinically relevant in vivo studies. Clin Pharmacokinet 2001;40:631-40.
30. Kariv I, Fereshteh MP, Oldenburg KR. Development of a miniaturized 384-well high throughput screen for the detection of substrates of cytochrome P450 2D6 and 3A4 metabolism. J Biomol Screen 2001;6:91-9.
31. Gao F, Johnson DL, Ekins S, et al. Optimizing higher throughput methods to assess drug-drug interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 in vitro using a single point IC(50). J Biomol Screen 2002;7:373-82.
32. Bjornsson TD, Callaghan JT, Einolf HJ, et al., and Pharmaceutical Research and Manufacturers of America Drug Metabolism/Clinical Pharmacology Technical Working Groups. The conduct of in vitro and in vivo drug-drug interaction studies: A PhRMA perspective. J Clin Pharmacol 2003;43:443-69.
33. Kremers P. Can drug-drug interactions be predicted from in vitro studies? Scientific World Journal 2002;2:751-66.
34. Use of antidepressants with other medications. In: Preskorn SH. Outpatient management of depression. Caddo, OK: Professional Communications; 1999:179-191.
35. Kaufman DW, Kelly JP, Rosenberg L, et al. Recent patterns of medication use in the ambulatory adult population of the United States: The Slone Survey. JAMA 2002;287:337-44.
36. Redfern WS, Wakefield ID, Prior H, et al. Safety pharmacology-A progressive approach. Fundam Clin Pharmacol 2002;16:161-73.